Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Schmid, KW; Helpap, B; Tötsch, M; Kirchmair, R; Dockhorn-Dworniczak, B; Böcker, W; Fischer-Colbrie, R.
Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate.
Histopathology. 1994; 24(3):233-239
Doi: 10.1111/j.1365-2559.1994.tb00515.x
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Tötsch Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Routinely processed normal, hyperplastic and neoplastic prostatic tissue was immunohistochemically investigated with antibodies against chromogranin A and B and secretogranin II. In normal and hyperplastic prostates all three peptides were immunolocalized in scattered neuroendocrine cells situated within the glandular epithelium. In 17 prostatic carcinomas with pronounced neuroendocrine differentiation and in a case of prostatic carcinoid, chromogranin B was the major component whereas chromogranin A and secretogranin II were virtually absent in poorly differentiated (grade III) tumours. Neuroendocrine differentiation in prostatic cancer is most likely to be associated with a poor clinical outcome; thus, chromogranin B appears to be a useful marker in the histopathological diagnosis of these neoplasms.
- Find related publications in this database (using NLM MeSH Indexing)
- Chromogranin A -
- Chromogranins - analysis
- Humans -
- Immunohistochemistry -
- Male -
- Prostate - chemistry
- Prostatic Hyperplasia - metabolism
- Prostatic Neoplasms - chemistry
- Proteins - analysis
- Find related publications in this database (Keywords)
- CHROMOGRANIN A
- CHROMOGRANIN B
- SECRETOGRANIN II
- SECRETONEURIN
- PROSTATE CARCINOMA
- NEUROENDOCRINE
- DIFFERENTIATION